RxDoctor Payments Data

Keith Sterett

Physician Assistant · Augusta, GANPI 1770033904

Payments from drug & device makers

$1,075in general payments, 2019–2025

Across 17 payments — averaging $63.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$212
  • Novo Nordisk$209
  • Abbott$174
  • Bayer$125
  • Biohaven Pharmaceuticals, Inc.$100
  • Lilly USA, LLC$99
  • plus $155 from 7 others

What the payments were for

  • Food & beverage$1,04497%
  • Other$303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,075 in reported general payments places this provider in the 65th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$3,610
Medicare patients
72
Services billed
222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol189$165,884
OzempicSemaglutide62$64,864
EliquisApixaban54$62,519
MounjaroTirzepatide43$40,801
JanuviaSitagliptin Phosphate53$34,355
TrulicityDulaglutide26$33,612
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$21,157
Breo ElliptaFluticasone/Vilanterol19$15,465
VraylarCariprazine Hcl12$14,502
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog41$12,641
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$10,971
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$10,738
Albuterol Sulfate HfaAlbuterol Sulfate251$9,154
JardianceEmpagliflozin13$8,950
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$212$180,885225 claims
Lilly USA, LLCMounjaro, Trulicity$99$74,41269 claims
Novo NordiskOzempic$209$64,86462 claims
PfizerEliquis$35$62,51954 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix$20$45,41057 claims
MerckJanuvia$14$34,35553 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →